Strategies in the development of peptide antagonists.
Department of Chemistry, University of Arizona, Tucson 85721.
V J
VJ
Hruby
D000595:Amino Acid Sequence; D000818:Animals; D015195:Drug Design; D005260:Female; D005934:Glucagon / Q000037:antagonists & inhibitors / Q000502:physiology; D008969:Molecular Sequence Data; D009479:Neuropeptides / Q000037:antagonists & inhibitors* / Q000737:chemistry; D010121:Oxytocin / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D011487:Protein Conformation; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors / Q000502:physiology; D018045:Receptors, Oxytocin; D017483:Receptors, Vasopressin / Q000187:drug effects / Q000502:physiology; D013004:Somatostatin / Q000037:antagonists & inhibitors; D013329:Structure-Activity Relationship; D014599:Uterus / Q000502:physiology
D009479:Neuropeptides; D017450:Receptors, Opioid, mu; D018045:Receptors, Oxytocin; D017483:Receptors, Vasopressin; D010121:Oxytocin; D013004:Somatostatin; D005934:Glucagon